ZYUS Life Sciences

ZYUS Life Sciences is a Canadian life sciences company focused on the development and commercialization of novel cannabinoid-based pharmaceutical drug candidates for pain management. Established in 2018, the company is listed on the TSXV as ZYUS. ZYUS is committed to advancing the science of well-being through rigorous scientific exploration, clinical research, and the development of innovative therapies. The company's primary goal is to obtain intellectual property protection to safeguard its novel therapies and enhance shareholder value.

With a focus on biopharma, biotechnology, healthcare, life sciences, and the pharmaceutical industry, ZYUS aims to secure regulatory approval for non-opioid-based pharmaceutical solutions. The company's vision is to have a transformational impact on patients' lives by providing alternative treatment options. ZYUS' dedication to obtaining regulatory approval and embracing innovative pharmaceutical solutions positions it as a potential leader in the evolving cannabinoid-based pharmaceutical market.

The most recent investment, in the form of a Post-IPO Debt investment, took place on 27 September 2024. The specific details of the investors in this round of investment are not explicitly mentioned in the provided information.